Products
Pre-made Itolizumab benchmark antibody ( Whole mAb, anti-CD6/TP120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-284
Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-284-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody |
| INN Name | Itolizumab |
| Target | TP120 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium |
| Conditions Approved | Plaque psoriasis |
| Conditions Active | Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis |
| Conditions Discontinued | Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis |
| Development Tech | na |
<